Abstract
Background Cocaine use accelerates HIV progression and worsens HIV outcomes. We assessed whether DNA methylation (DNAm) in blood mediates the association between cocaine use and HIV severity in a veteran population.
Methods We analyzed 1,435 HIV-positive participants from the Veterans Aging Cohort Study Biomarker Cohort. HIV severity was measured by the Veteran Aging Cohort Study index (VACS index). We assessed the effect of cocaine use on VACS index and mortality among the HIV-positive participants. We selected candidate mediators from 408,583 CpGs that were both significantly associated with persistent cocaine use and VACS index by epigenome-wide association (EWA) scans. Mediation analysis was conducted on the selected CpGs and joint mediation effect of multiple CpGs were estimated.
Results More frequent cocaine use was significantly associated with higher VACS index (p=2.7E-04) and cocaine use increased the risk of 10-year mortality (hazard ratio=1.10, p=0.011) with adjustment of confounding factors. Based on the EWA scan, 15 candidate mediator CpGs were selected and 12 CpGs showed significant mediation effect with each explained 11.3%-29.5% of the variation. The joint mediation effect of these 12 CpGs accounted for 47.2% of cocaine’s effect on HIV severity. Genes harboring these 12 CpGs are involved in antiviral response (IFIT3, IFITM1, NLRC5, PLSCR1, PARP9) and HIV progression (CX3CR1, MX1). Furthermore, these genes were enriched in pathways involving in viral process (p=7.76E-08) and response to cytokine (p= 9.88E-07).
Conclusions DNAm played a mediation role between cocaine use and HIV severity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by the National Institute on Drug Abuse (R03DA039745, R01DA038632, R01DA047063, R01DA047820).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Methylation data is available on GEO
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100264